MONTHLY INFORMATION REGARDING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING OF THE SHARE CAPITAL
as per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

<table>
<thead>
<tr>
<th>Date</th>
<th>Previous total number of shares making of the share capital</th>
<th>Previous total number of voting rights</th>
<th>Change explanation</th>
<th>New total number of shares making of the share</th>
<th>New total number of voting rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>31/08/2022</td>
<td>11.881.902</td>
<td>20 424 893</td>
<td>Fluctuation in the double voting rights</td>
<td>11.881.902</td>
<td>20 424 742</td>
</tr>
</tbody>
</table>

FOR MORE INFORMATION, CONTACT:

VETOQUINOL
Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At June 30th 2022, Vetoquinol employs 2621 people. Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).